Latest From ProStrakan AB
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
Appointments: Novartis And GSK Announce New R&D Heads, LNC Therapeutics Gets A New CEO, Plus Announcements From Zelluna and BC Platforms
This week's appointments include new R&D heads at Novartis and GSK, while LNC Therapeutics gets a new CEO, Plus announcements from Zelluna and BC Platforms.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.
CDER safety staff will present the case for adding labeling about the condition during a March 14 Pediatric Advisory Committee review of pediatric adverse events for 16 drugs, including Hoffman-LaRoche’s Kytril, a member of the 5-HT3 receptor antagonist class.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- ProStrakan AB
- Senior Management
- Contact Info
Phone: (46) 40 15457
Malmo, 216 18